spacer
home > epc > media info
MEDIA INFORMATION

Click here to view the EPC media pack

EPC offers an industry-leading platform, which includes:
  • An international readership of pharma and biotech decision makers, plus full-service and speciality CROs, in print
    and online
  • Strong, opinion-led editorial comment and analysis
  • Affiliation with international trade events and conferences
  • An impressive record of long-term advertising partnerships
    and a loyal affiliate network
  • Multimedia presence to reach a global audience
Each edition of EPC runs a number of expert, discussion-based features on the latest contract research and outsourcing moves.
Topics regularly covered include:
  • CRO market analysis
  • Biopharmaceutical development
  • Non-clinical pharmacology/toxicology
  • Laboratory services (bioanalytical labs, central labs)
  • Biosimilars development
  • Biomarkers and assay development
  • Data management
  • Biostatistics
  • Pharmacovigilance
  • Chemistry, manufacturing, controls
  • Strategic and regulatory planning
  • Pricing and market access
  • Contract planning
  • Outsourcing models (eg full service, functional service provider)
  • Supplier selection
  • Managing supplier relationships
  • Procurement practices
  • Technical innovation
  • Business process management
  • CRO performance metrics
spacer



Published quarterly in
February, May,
August, and November
 
Industry Events

DIA 2019 Global Annual Meeting

23-27 June 2019, San Diego Convention Center

DIA 2019 is more than just a meeting: it’s where brilliant minds come together to create solutions. Thousands of global innovators will convene to engage in discussions on today’s hottest topics in the life sciences field, propose ways to combat daily challenges, and network to create lasting connections.
More info >>

 
News and Press Releases

MedPharm announce expansion of partnership with Palvella Therapeutics in developing a new treatment for the debilitating rare disease, pachyonychia congenita

MedPharm Ltd have announced the expansion of their partnership with Palvella Therapeutics, Inc., a Philadelphia-based biopharmaceutical company focused on developing and commercialising therapies for debilitating, rare genetic diseases. To date, MedPharm has employed its world-renowned specialist formulation expertise to support Palvella’s development of a novel, high-strength rapamycin topical formulation for application to the skin (PTX 022) as a disease-modifying treatment for pachyonychia congenita (PC). Most recently, MedPharm has made arrangements to manufacture the clinical (IMP) batches for use in Palvella’s upcoming Phase 2/3 clinical study.
More info >>

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement